Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis / 中国实验方剂学杂志
Chinese Journal of Experimental Traditional Medical Formulae
; (24): 14-20, 2020.
Article
Dans Zh
| WPRIM
| ID: wpr-873047
Responsable en Bibliothèque :
WPRO
ABSTRACT
Objective:
To analyze the clinical efficacy of Shufeng Jiedu Capsule (SFJD capsule) combined with western medicine in the treatment of common coronavirus disease-2019 (COVID-19).Method:
By the usage propensity score matching, the clinical data of COVID-19 patients with common COVID-19 admitted to Wuhan third hospital from January 27, 2020 (solstice) to March 5, 2020, were screened out. Thirty-four patients with SFJD capsule combined with conventional therapy according to the inclusion and exclusion criteria were enrolled in treatment group, and 34 patients treated with conventional therapy were enrolled in control group. The disappearance rate of main symptoms (fever, cough, expectoration and fatigue), days of syndrome disappearance, effective rate and disappearance rate of other symptoms, laboratory indexes before treatment and after 7 days′ treatment, effective rate of computed tomography (CT) of the lungs, rate of COVID-19 severe transformation and hospitalization time between the two groups were compared.Result:
The baseline data between the two groups showed no statistically significant difference, and was comparable. After 7 days of treatment, the symptom disappearance rate of cough, sputum, fatigue, chest tightness and panting in treatment group was significantly higher than that in control group (P<0.05). The average days of disappearance of main symptoms in treatment group was significantly less than that in control group (P<0.05). The effective rate of main symptom was significantly higher than control group (P<0.05). In treatment group, 8.8%(3/34) of the patients were transferred to severe disease, while 26.5%(9/34) of the patients in control group were transferred to severe disease, with statistically significant differences. After treatment for 7 days, lymphocytes in treatment group significantly increased (P<0.05), C-reactive protein significantly decreased (P<0.05), procalcitonin level significantly decreased (P<0.05), and D-dimer level significantly decreased (P<0.05), while lymphocytes in control group significantly increased (P<0.05), and c-reactive protein significantly decreased (P<0.05). The improvement rate of pulmonary CT in treatment group was 91.2%(31/34), which was significantly higher than 70.6%(24/34) in control group (P<0.05). After treatment, both groups were cured and discharged, the average length of stay in treatment group was (15.53±2.63) d, which was (16.35±4.98) d in control group,with no statistically significant difference. No adverse events occurred in treatment group, but 3 cases occurred in control group.Conclusion:
SFJD capsule combined with western medicine can significantly improve the clinical symptoms of normal COVID-19 patients, such as cough, sputum, fatigue, chest distress and shortness of breath, alleviate the main symptoms effectively, regulate the expressions of relevant peripheral inflammation, promote the absorption of lung inflammation, and improve the cure rate, which indicates that SFJD capsule can be effectively in the treatment of patients with common COVID-19.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Experimental Traditional Medical Formulae
Année:
2020
Type:
Article